Table 2. Synthetic peptides currently produced by the pharmaceutical industry and strategy of synthesis employed.

Peptide

Nr amino acid residues

Amount

Legal status

Strategy of synthesis

 ACTH (1-24)

24

50-100 kg

Commercial

SPS

 Atosiban

9

50-100 kg

Commercial

SPS

 Cetrorelix

10

10-100 kg

Commercial

SPS

 Eptifibatide

7

>200 kg

Commercial

SPS

 Exendine

39

Phase III

SPPS

 Fuzeon-20

36

4000 kg

Approved

SPPS and Frag

 LH_RH

10

150-200 kg

Commercial

SPS and SPPS

 Buserellin

9

NIA

Commercial

SPPS

 Dislorelin

9

NIA

Commercial

SPPS

 Coselin

10

NIA

Commercial

SPPS

 Leuprolide

9

250 kg

Commercial

SPPS

 Triptorelin

10

NIA

Commercial

SPPS

 Parathyroid hormone

34

NIA

Approval

SPPS

 Pramlintide

37

>10 kg

Phase III

SPS and SPPS

 Salmon calcitonin

32

NIA

Commercial

SPS and SPPS

 Somatostatin

14

NIA

Approved

SPS and SPPS

 Lanreotide

8

100-200 kg

Approval

SPPS

 Octreotide

8

100-200 kg

Approval

SPS

 Theratope

43

NIA

Phase III

SPS and Frag

 Thymalfasin

28

NIA

Approval

SPPS

 Thymosine alpha-1

28

200-400 kg

Approval

SPPS

 Vassopresin analogs

 Desmopressin

9

5-10 kg

Approved

SPS and SPPS

 Lypressin

9

5-10 kg

Approved

SPS

 Pitressin

9

5-10 kg

Approved

SPS

 Terlipressin

9

5-10 kg

Approved

SPS and SPPS

 Zinconotide

25

1-5 kg

Phase III

SPPS